Will the Imfinzi·Imjudo combo be reimb within the year?
By Eo, Yun-Ho | translator Alice Kang
24.10.02 05:08:24
가나다라
0
AstraZeneca Korea applies for reimbursement listing of the combination in June
Whether it will be deliberated by CDDC gains attention…the combination demonstrated potential for long-term survival
Whether the combination of the immuno-oncology drugs Imfinzi and Imjudo will be reimbursed for liver cancer in Korea is gaining attention.
In June, AstraZeneca Korea submitted an application for the reimbursement of the PD-L1 inhibitor Imfinzi (durvalumab) and CTLA-4 inhibitor Imjudo (tremelimumab) combination for liver cancer.
Therefore, it remains to be seen if it will be presented to the Health Insurance Review and Assessment Service’s Cancer Disease Review Committee within this year.
Imjudo received approval in combination with Imfinzi from the Ministry of Food and Drug Safety in June last year.
The first target indication for the combination wa
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)